US Medicare lays out timeline for third round of drug price negotiations
(Reuters) -The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year.
For the first time, the list would include drugs payable under Medicare Part B - which covers medicines administered in a doctor's office or hospital - in addition to prescription drugs covered under Medicare Part D, CMS said.
WHY IT'S IMPORTANT
The drug price negotiation process was established under President Joe Biden's signature Inflation Reduction Act in 2022. The first round included drugs among the most expensive for Medicare insurance plans covering people aged 65 years and older or with disabilities.
After facing criticism from the pharmaceuticals industry, President Donald Trump's administration had previously promised "greater transparency" in the process.
CONTEXT
CMS announced prices for ten drugs in August 2024, in its first round of cuts following a year of talks. The second round, which includes negotiations for 15 drugs such as Novo Nordisk's blockbuster diabetes medicine Ozempic, is currently underway and a final decision on prices is due by November 30, 2025.
Negotiated prices for the third round will take effect on January 1, 2028. Additionally, CMS said it was seeking public comment on various topics to enhance transparency and reduce the administrative burden for participating manufacturers.
Earlier in the day, Trump signed a wide-reaching executive order directing drugmakers to lower their prices to align with what other countries pay, a measure that analysts and legal experts have cautioned will be difficult to implement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success, NVO is developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced candidate in Novo Nordisk's pipeline is CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy. CagriSema met the primary endpoint of statistically significant weight loss in two late-stage studies. The company is already planning its regulatory submission in 2026. Novo Nordisk is also developing an early-stage candidate, Amycretin, a unimolecular GLP-1 and amylin receptor agonist, which had outperformed Wegovy in a phase I study. Novo Nordisk has also been pursuing licensing deals and acquisitions to further expand its obesity pipeline. In 2023, it acquired Inversago Pharmaceuticals, which added a small-molecule oral CB1 inverse agonist, monlunabant, to its pipeline. Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, type II diabetes (T2D) and other cardiometabolic diseases. Eli Lilly LLY is NVO's fierce competitor in the obesity space, which markets its tirzepatide medicines as Mounjaro for T2D and Zepbound for obesity. Like NVO, LLY is also evaluating several next-generation weight loss candidates. Lilly recently reported first phase III success of its oral GLP-1 candidate, orforglipron, which showed significant weight reduction potential in the late-stage study. Regulatory filings for orforglipron are planned in 2025 and 2026. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. VKTX initiated a mid-stage study on the oral formulation of the candidate earlier this year and is on track to start the late-stage study on the subcutaneous version soon. Year to date, Novo Nordisk shares have plunged 15.5% compared with the industry's decline of 2.3%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading above its 50-day moving average, but below its 200-day moving average. Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 17.37 forward earnings, which is higher than 14.95 for the industry. However, the stock is trading much below its five-year mean of 29.25. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.80 to $3.84 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.60 to $4.64. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.56% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
New York Post
38 minutes ago
- New York Post
Doctors warn about ‘very real risks' of Ozempic ‘golden dosing' trend: ‘Recipes for disaster'
GLP-1 users might be jabbing for weight loss, but many are trying to combat cash loss by squeezing an extra dose out of their medication. The trend, dubbed 'golden dosing,' has been hyped by social media users as a way to get more bang for your buck. But doctors are warning it could be dangerous — and even set back your weight loss goals. 'Using a medication outside of its prescribed method is always risky — and in this case, especially unnecessary,' Dr. Michael Snyder, medical director of Bariatric Surgery at Rose Medical Center and an in-house expert at FuturHealth, told The Post. Advertisement 4 Surveys show that roughly 1 in 8 US adults have tried GLP-1 drugs. millaf – What is golden dosing? GLP-1 drugs like Ozempic, Mounjaro and Wegovy come in injectable pens that contain four doses, with each device lasting about a month. But some users have noticed that their pens often have leftover liquid after their final jab. This extra medication isn't a mistake. It's designed to allow for an initial flow check and to ensure that each of the four doses is accurate and complete. Advertisement Nevertheless, some TikTok users are extracting this leftover liquid with syringes and needles, using it as a fifth and final 'golden dose.' With out of pockets costs for these drugs sometimes topping $1,000 a pen, pulling out the extra medication has become a way to cut back a bit on exorbitant costs. But experts say the trend raises some major red flags. 'The 'golden dose' is more of a cost-saving strategy than one focused on safety and effectiveness,' Dr. Shiara Melissa Ortiz-Pujols, a bariatric surgeon at Northwell Health, told The Post. Advertisement 4 Typically, GLP-1 pens contain four doses. Fernanda – A dose of confusion GLP-1 pens deliver pre-measured doses that are carefully prescribed by healthcare providers based on factors like weight and health status. 'Any deviation — even what might seem like a 'small' one — can disrupt how your body responds,' Snyder warned. Advertisement GLP-1s are typically titrated, meaning the dosage is gradually increased over time to help the body adjust to the drug. 'As we increase the dose, we expect greater effectiveness, but we also face a higher risk of severe side effects,' Ortiz-Pujols explained. 4 Taking too much of the medication can lead to painful gastrointestinal effects. – Increasing your dose too quickly or taking inconsistent amounts week to week can worsen side effects, she said. It could also complicate your treatment plan, making it difficult for doctors to accurately track how your body is responding to the medications and make informed adjustments based on your personal needs, Snyder cautioned. From hack to hazard Attempting to recover leftover medication using a syringe also carries 'very real risks' for your health, Snyder said. Even minor miscalculations can lead to overdoses, triggering symptoms like nausea, vomiting and even pancreatitis. Advertisement 4 There's a major risk for bacterial growth if the syringe isn't completely sterile. Jo Panuwat D – On the flip side, underdosing can blunt the drug's effectiveness, resulting in weight regain and glucose instability. 'To put it simply, how comfortable would you feel using what you think is the 'right amount' of a blood pressure medication, a blood thinner, or a narcotic?' Snyder posed. 'All of those could be recipes for disaster. This situation is no different.' A hidden danger Advertisement The trend also poses a serious risk of infection. 'GLP-1 pens are designed to be used as a sealed system,' Snyder said. 'Using an external syringe breaks sterility, exposing the medication to bacteria during handling — even from clean-looking surfaces or hands.' This can lead to local infections at the injection site or even systemic infections, Snyder noted, emphasizing that the risk is particularly high for those who reuse syringes or directly touch the drug solution. 'There's no reliable way to make this DIY method safe,' Snyder said. 'That's why these pens are single-use and designed for highly controlled administration.'
Yahoo
2 hours ago
- Yahoo
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday. Shares of AstraZeneca and BioNTech were marginally up, while those of GSK and Sanofi declined 1% and 0.2%, respectively. U.S. vaccine maker Moderna fell slightly in premarket trading, while Novavax and Pfizer traded marginally said that while the unprecedented dismissals of all members of the Advisory Committee on Immunization Practices (ACIP) represented a risk for vaccine manufacturers, investors would wait to see any impact on the companies. Since he was appointed as U.S. health secretary, Kennedy, a vaccine skeptic, has made several changes to reshape the regulation of vaccines, food and medicine. However, firing members of the ACIP remains his most far-reaching move yet. Some analysts expressed concerns that the new committee members, who have not been named, might be more sympathetic to Kennedy's views on vaccines, an idea shared by scientific experts and doctors. While the makeup of a reconstituted ACIP is to be determined, "new members will likely be sympathetic to at least some of RFK's beliefs regarding alleged dangers of vaccines", Leerink analyst Daina Graybosch said in a note. Graybosch said that the move could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development. Kennedy's decision came less than three weeks before the next panel meeting set for June 25 to June 27 and is slated to discuss recommendations for who should receive vaccines for diseases like respiratory syncytial virus. It is unclear when Kennedy will announce the new members, who the agency said are under consideration, or whether the agenda will follow the meeting description posted on the Federal Register on Monday. "It's hard to assess what the ultimate impact may be on vaccine makers as we don't have much clarity on who will take these members' places on the Committee," said James Harlow, senior vice president at Novare Capital Management, which owns Pfizer shares. Harlow added that sentiment around vaccine makers has been negative coming into the news. "It would appear much has already been baked into the prices of these stocks," he said. BMO Capital Markets analyst Evan Seigerman said that RFK Jr.'s views have consistently skewed negatively to groups like ACIP, making the decision "less shocking in our eyes." Seigerman added that while the announcement introduces additional uncertainty into the sector, it likely represents "more headline risk than a true fundamental change at the agency." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
